Adicet Bio, Inc. (0HX7.L)
USD 0.58
(16.85%)
USD 0.58
(16.85%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -6.09 Million USD | -130.52% |
| 2022 | 19.98 Million USD | 105.35% |
| 2021 | 9.73 Million USD | -45.65% |
| 2020 | 17.9 Million USD | 1957.82% |
| 2019 | 870 Thousand USD | -89.26% |
| 2018 | 8.1 Million USD | 162119.98% |
| 2017 | -5000.00 USD | 0.0% |
| 2016 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -1.6 Million USD | 2.97% |
| 2024 Q1 | -1.65 Million USD | 2.25% |
| 2023 Q1 | -1.81 Million USD | -1.91% |
| 2023 FY | -6.09 Million USD | -130.52% |
| 2023 Q4 | -1.68 Million USD | 28.07% |
| 2023 Q3 | -2.34 Million USD | -2.8% |
| 2023 Q2 | -2.28 Million USD | -25.84% |
| 2022 FY | 19.98 Million USD | 105.35% |
| 2022 Q4 | -1.78 Million USD | -52.61% |
| 2022 Q2 | -1.06 Million USD | -104.43% |
| 2022 Q1 | 23.99 Million USD | 338.79% |
| 2022 Q3 | -1.16 Million USD | -9.68% |
| 2021 FY | 9.73 Million USD | -45.65% |
| 2021 Q2 | 4.81 Million USD | 220.92% |
| 2021 Q4 | 5.46 Million USD | 59.46% |
| 2021 Q1 | -3.98 Million USD | -173.59% |
| 2021 Q3 | 3.42 Million USD | -28.77% |
| 2020 Q2 | 7.46 Million USD | 273.25% |
| 2020 Q1 | 2 Million USD | 1.57% |
| 2020 FY | 17.9 Million USD | 1957.82% |
| 2020 Q4 | 5.41 Million USD | 78.67% |
| 2020 Q3 | 3.02 Million USD | -59.44% |
| 2019 Q3 | -7.04 Million USD | -313.29% |
| 2019 FY | 870 Thousand USD | -89.26% |
| 2019 Q1 | 2.76 Million USD | 0.0% |
| 2019 Q2 | 3.3 Million USD | 19.32% |
| 2019 Q4 | 1.96 Million USD | 127.94% |
| 2018 FY | 8.1 Million USD | 162119.98% |
| 2017 FY | -5000.00 USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| uniQure N.V. | 2.21 Million USD | 375.305% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 101.684% |
| Dynavax Technologies Corporation | 182.11 Million USD | 103.348% |
| Illumina, Inc. | 2.74 Billion USD | 100.222% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 100.116% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 100.33% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 100.04% |
| Biogen Inc. | 7.3 Billion USD | 100.084% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 135.21% |
| bluebird bio, Inc. | -4.03 Million USD | -51.315% |
| Imunon, Inc. | -720 Thousand USD | -746.939% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 100.281% |
| Myriad Genetics, Inc. | 476.4 Million USD | 101.28% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 100.558% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 101.164% |
| Nektar Therapeutics | 53.47 Million USD | 111.403% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 141.219% |
| Perrigo Company plc | 1.68 Billion USD | 100.363% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | -1848.243% |
| Editas Medicine, Inc. | -99.52 Million USD | 93.873% |
| Verastem, Inc. | -62 Thousand USD | -9735.484% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 100.023% |
| Waters Corporation | 1.76 Billion USD | 100.346% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 80.435% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 36.253% |
| Heron Therapeutics, Inc. | 10.04 Million USD | 160.725% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 69.044% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 100.32% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 86.546% |
| Evolus, Inc. | 140.52 Million USD | 104.339% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 92.844% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 100.054% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 108.346% |
| FibroGen, Inc. | 128.9 Million USD | 104.731% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 100.176% |
| OPKO Health, Inc. | 318.12 Million USD | 101.917% |
| Homology Medicines, Inc. | -7.22 Million USD | 15.645% |
| Geron Corporation | -123.5 Million USD | 95.062% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 100.402% |
| Exelixis, Inc. | 1.75 Billion USD | 100.347% |
| Viking Therapeutics, Inc. | -292 Thousand USD | -1988.356% |
| Anavex Life Sciences Corp. | - USD | Infinity% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 98.471% |
| Zoetis Inc. | 5.83 Billion USD | 100.105% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 102.494% |
| Abeona Therapeutics Inc. | 302 Thousand USD | 2119.205% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 100.071% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | -1912.541% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 100.783% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 101.281% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 100.957% |
| Blueprint Medicines Corporation | 236.58 Million USD | 102.578% |
| Insmed Incorporated | 239.63 Million USD | 102.545% |
| TG Therapeutics, Inc. | 219.1 Million USD | 102.783% |
| Incyte Corporation | 3.44 Billion USD | 100.177% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 101.773% |